Hepatic Encephalopathy (HE) - Management

Definition & Overview

• Sleisenger and Fordtran's GI and Liver Disease, p. 1815
• Bradley and Daroff's Neurology in Clinical Practice, p. 1782

Classification

By Underlying Disease (Type)

By Severity - West Haven Criteria & SONIC Classification

By Time Course

• Episodic - recurrent episodes within 6 months
• Persistent - behavioral alterations always present with relapses of overt HE
• Spontaneous vs. Secondary - presence or absence of a precipitating factor

Pathophysiology

1. Ammonia toxicity - Produced mainly in the colon from bacterial protein metabolism and by enterocytes from glutamine. Normally cleared by hepatocytes; in cirrhosis, reduced hepatocyte function + portosystemic shunting leads to hyperammonemia. Ammonia crosses the blood-brain barrier, causing astrocyte swelling, cytotoxic brain edema, and direct neuroinflammation.
2. GABA-benzodiazepine system - Increased astrocyte (peripheral-type) benzodiazepine receptor sensitivity enhances GABA-A activation, with neurosteroids (allopregnanolone, tetrahydrodeoxycorticosterone) amplifying this in a feed-forward manner.
3. Manganese deposition - Manganese accumulates in the basal ganglia (seen as T1 hyperintensity on MRI at the pallidum, cerebral peduncles, substantia nigra); causes dopaminergic dysfunction.
4. Other factors - Serotonin, nitric oxide, circulating opioid peptides, altered amino acid profiles, short-chain fatty acids, pro-inflammatory cytokines. Hyperammonemia-inflammatory interaction is now considered a major driver.

Precipitating Factors (Must Identify and Treat)

• GI bleeding (most common)
• Infection / sepsis (including spontaneous bacterial peritonitis)
• Electrolyte disturbances - hypokalemia, hyponatremia, dehydration
• Medications - benzodiazepines, opioids, sedatives, diuretics
• Dietary protein excess
• Constipation
• Renal failure / hepatorenal syndrome
• Portosystemic shunts (TIPS or spontaneous)

Diagnosis

• Clinical diagnosis based on signs/symptoms in the appropriate setting of liver disease. No single lab test confirms HE.
• Blood ammonia: Elevated in up to 90%, but neither sensitive nor specific. Arterial ammonia offers no advantage over venous in chronic liver disease.
• Neuropsychometric testing for covert/minimal HE:
  • PSE Syndrome Test (Number Connection Tests A & B, serial dotting, line tracing, Digit Symbol Test)
  • Stroop test / EncephalApp (smartphone-based, validated for covert HE)
  • Critical flicker frequency (CFF)
• EEG: Characteristic bursts of high-amplitude (100-300 µV), low-frequency (1.5-2.5 Hz) waves with frontal predominance in severe HE.
• MRI: T1 hyperintensity in the pallidum (manganese deposition). MR spectroscopy shows elevated glutamine/glutamate (Glx) and reduced myoinositol and choline.
• Neuroimaging is primarily used to exclude structural lesions (subdural hematoma, Wernicke's encephalopathy, etc.).

Management

1. Identify and Correct Precipitating Factors

2. Dietary Management

• Do NOT restrict dietary protein in stable chronic HE - this was previously recommended but is now known to worsen outcomes by promoting catabolism in already nutritionally depleted cirrhotics.
• Target 1.2-1.5 g/kg/day of protein.
• Prefer vegetable-based and dairy proteins over animal protein, as they generate less ammonia.
• Branched-chain amino acids (BCAAs): Infusion of BCAAs has shown benefit without increased mortality in patients with HE, especially those intolerant of oral protein intake (Rosen's Emergency Medicine, p. 1235).
• Small, frequent meals and a late evening snack reduce protein catabolism.

3. Ammonia-Lowering Therapies

Lactulose (First-line)

• Mechanism: Non-absorbable disaccharide metabolized by colonic bacteria to organic acids (lactic, acetic), lowering colonic pH. Acidic pH converts NH₃ to NH₄⁺ (non-absorbable), reduces ammonia production, and promotes colonic transit (cathartic effect).
• Dose: 30-60 g/day (typically 15-30 mL 2-4 times daily) orally; titrate to 2-3 soft stools per day.
• Acute episode: Can be given as enemas (300 mL lactulose + 700 mL water) in obtunded patients.
• Caution: Over-use causes diarrhea, dehydration, and hypernatremia, which can worsen HE.

Rifaximin (First-line for secondary prophylaxis)

• Mechanism: Minimally absorbed broad-spectrum antibiotic. Reduces ammonia-generating gut bacteria.
• Dose: 400 mg PO every 8 hours (or 550 mg twice daily for prophylaxis).
• Approved specifically for prevention of recurrent overt HE in patients already on lactulose.
• Superior to lactulose alone for maintaining remission; significantly reduces hospitalizations.
• Bradley and Daroff's Neurology in Clinical Practice - rifaximin used in the landmark multicenter trial leading to FDA approval.

Other Antibiotics (Historical / Alternative)

• Neomycin: Reduces ammonia-producing gut bacteria; largely replaced by rifaximin due to systemic toxicity (nephrotoxicity, ototoxicity).
• Metronidazole: Second-line alternative; peripheral neuropathy limits long-term use.

4. Management of Overt / Acute HE

• Admit for monitoring, correct precipitants aggressively.
• Ensure airway protection in Grade 3-4 HE (intubation if necessary to prevent aspiration).
• Correct hypokalemia (promotes renal ammonia generation) and metabolic alkalosis.
• Administer lactulose via nasogastric tube or enemas in obtunded patients.
• Avoid benzodiazepines and sedatives (worsen HE via GABA-A potentiation) - use haloperidol in low doses for agitation if absolutely necessary.
• Treat cerebral edema in acute liver failure (Grade 4): mannitol 0.5-1 g/kg IV, head elevation, avoid hyperthermia, consider ICP monitoring in severe cases.
• In acute liver failure, consider N-acetylcysteine (for acetaminophen-induced ALF), early liver transplant evaluation.

5. Treatment of Minimal / Covert HE

• Treat if quality of life is impaired or driving safety is at risk.
• Lactulose and rifaximin both effective.
• Advise patients against driving while impaired (studies show worst on-road driving performance in minimal HE patients).

6. Preventing Recurrence (Secondary Prophylaxis)

• Rifaximin 550 mg twice daily + lactulose is the standard combination.
• Identify and address modifiable risk factors (large portosystemic shunts, ongoing alcohol use, malnutrition).
• TIPS (transjugular intrahepatic portosystemic shunt) - reduces portal hypertension but can worsen HE; use with caution in patients with pre-existing HE.

7. Novel / Adjunct Therapies

• Zinc supplementation: Zinc deficiency is common in cirrhosis; zinc is required for urea cycle enzymes. Supplementation may reduce ammonia levels.
• Probiotics: Alter gut microbiota composition, may reduce ammonia production; evidence emerging.
• L-ornithine L-aspartate (LOLA): Stimulates urea cycle and glutamine synthetase, used in some countries; evidence mixed but IV formulation may benefit acute HE.
• Ornithine phenylacetate: Increases urinary ammonia excretion; under investigation.
• Extracorporeal liver support (MARS, Prometheus): May temporarily reduce ammonia in ALF/ACLF; a 2025 Cochrane review (PMID 42047248) noted insufficient evidence to confirm mortality benefit from liver support systems in acute liver failure.

8. Definitive Treatment

• Liver transplantation (LT) is the only definitive treatment. LT generally reverses HE, and the T1 MRI manganese signal abnormalities regress after successful transplantation.
• LT evaluation should be initiated early in patients with recurrent or persistent HE.

Summary Algorithm

HE suspected (altered mental status + liver disease)
        ↓
Exclude other causes (hypoglycemia, hyponatremia, intracranial bleed, drugs)
        ↓
Grade severity (West Haven / SONIC)
        ↓
Identify & TREAT precipitating factors (GI bleed, infection, electrolytes, medications)
        ↓
Start ammonia-lowering therapy:
  - Lactulose (30-60 g/day) → 2-3 soft stools/day
  - Add rifaximin (400-550 mg bid/tid) for recurrent/refractory HE
        ↓
Nutritional support (1.2-1.5 g/kg protein/day, BCAA if intolerant)
        ↓
Prophylaxis: Rifaximin + lactulose for secondary prevention
        ↓
Assess for liver transplantation

Key Points

• Blood ammonia is neither sensitive nor specific - the diagnosis of HE is clinical.
• Protein restriction is NOT recommended - it worsens outcomes.
• Rifaximin + lactulose is the evidence-based combination for recurrent overt HE.
• Proton pump inhibitor (PPI) use increases risk of HE in cirrhotics (PMID 40812534, 2025 meta-analysis) - minimize unnecessary PPI prescriptions in cirrhotic patients.
• Driving impairment begins at the minimal/covert HE stage - counsel patients accordingly.
• LT is the only cure.

• Sleisenger and Fordtran's GI and Liver Disease, Chapter 94 (pp. 1815-1820)
• Bradley and Daroff's Neurology in Clinical Practice, Chapter 84 (pp. 1781-1784)
• Rosen's Emergency Medicine, Chapter on Hepatic Disorders (p. 1235)
• PubMed 2025: Jaber H et al. (PMID 40812534) - PPI use increases HE risk in cirrhosis (meta-analysis)
• PubMed 2026: Martí-Carvajal AJ et al. (PMID 42047248) - Liver support systems in acute liver failure (Cochrane review)